Page 21 - Securities Note News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Latécoère announces the launch of a share capital increase with shareholders' preferential subscription rights for an amount of approximately €193.4 million, which may be extended to approximately €222.4 million... Subscription ratio: 4 new shares for 1 existing share Theoretical value of the preferential subscription rights: 0.98 Trading period for preferential subscription rights: from July 16 th to July 26 th to July 28 Subscription commitment from Searchlight Capital Partners for the total amount of the transaction Not to be published, distributed or circulated directly or indirect...

(1) DJ Affluent Medical announces the success of its initial public offering on the Euronext Paris regulated market. Affluent Medical Affluent Medical announces the success of its initial public offering on the Euronext Paris regulated market. 09-Jun-2021 / 20:12 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. =---------------------------------------------------------------------------------------------------------------------- PRESS RELEASE Aix-en-Provence, 9 June 2021 - 8.00 p.m. AFF...

Affluent Medical announces the success of its -2- DJ Affluent Medical announces the success of its initial public offering on the Euronext Paris regulated market. Affluent Medical Affluent Medical announces the success of its initial public offering on the Euronext Paris regulated market. 09-Jun-2021 / 20:12 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. =---------------------------------------------------------------------------------------------------------------------- PRESS RELEASE ...

DJ Affluent Medical launches its IPO on the regulated Euronext Paris market. Affluent Medical Affluent Medical launches its IPO on the regulated Euronext Paris market. 27-May-2021 / 08:00 CET/CEST

This transaction will accelerate the development of the Company and its portfolio and extend its financial horizon to the end of 2022, beyond major clinical milestones expected in the next 18 months Regulatory